B. breve

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Overall, Bifidobacterium breve (B. breve) research has most heavily focused on (1) early-life microbiome development and host–immune interactions, reflecting its prominence in the infant gut, and (2) mechanistic and translational studies linking B. breve to gut–brain and gut–immune pathways. Across the abstracts, the most developed experimental areas include neurobehavioral outcomes (depression- and cognition-related phenotypes) and inflammation-associated intestinal disease models, alongside broader reviews describing age-related shifts in bifidobacterial species and their metabolite production (e.g., short-chain fatty acids and other bioactives). A recurring theme is that B. breve effects appear strain-specific and are frequently attributed to changes in microbial community structure and microbial metabolism—particularly tryptophan-derived indoles and related signaling pathways.

The strongest evidence in the provided set supports two conclusions. First, there is emerging human randomized controlled trial evidence for a specific strain, B. breve CCFM1025, as an adjunctive “psychobiotic” in major depressive disorder, with statistically significant improvements versus placebo on depression rating scales and associated changes consistent with altered serotonergic/tryptophan metabolism and gut microbiome features. Second, robust preclinical evidence supports anti-inflammatory and immunomodulatory actions of B. breve in the gut, including suppression of colitis-associated tumorigenesis in mice via macrophage differentiation toward homeostatic phenotypes; this effect is mechanistically linked to B. breve–associated indole-3-lactic acid engaging AhR/AKT signaling. In parallel, multiple mouse studies suggest potential cognitive benefits (e.g., Alzheimer’s disease model improvements with B. breve A1), with accompanying reductions in neuroinflammatory gene expression, though these findings remain primarily preclinical.

Key gaps include the need for larger, well-powered, independently replicated human trials across indications (depression, cognition/aging, gastrointestinal inflammatory conditions), with standardized endpoints, longer follow-up, and careful control of diet, medications, and baseline microbiome state. More research is also needed to disentangle strain-level specificity (since effects do not generalize across bifidobacterial strains), to establish dose–response and durability, and to validate causal mechanisms in humans (e.g., whether tryptophan/indole metabolites such as indole-3-lactic acid mediate clinical benefit and through which host receptors). Finally, early-life studies would benefit from longitudinal designs linking infant B. breve colonization patterns to later immune and neurodevelopmental outcomes, clarifying when supplementation is beneficial, neutral, or potentially context-dependent.

1. What conditions has B. breve been studied for?

  • Major depressive disorder (MDD): Studied as a “psychobiotic” strain B. breve CCFM1025 in a randomized trial in adults with MDD.

  • Mild cognitive impairment (MCI) / cognitive decline: Studied in older adults using B. breve A1 (MCC1274) in randomized, double-blind, placebo-controlled trials (16 and 24 weeks).

  • Alzheimer’s disease (AD)–related cognitive dysfunction: Studied in AD model mice with B. breve A1, including testing of non-viable components and the metabolite acetate.

  • Cognition/learning in healthy animals: Studied in mice using B. breve 1205 (alongside another species/strain, B. longum 1714).

  • Colitis-associated colorectal cancer (CAC) / colitis-driven tumorigenesis: Studied in mice; B. breve supplementation evaluated for effects on colitis symptoms, macrophage biology, and tumor development.

  • General gastrointestinal disorders and infection-related outcomes: Mentioned in review-style abstracts as common applications of Bifidobacterium strains including B. breve (not necessarily strain-specific clinical proof in the provided text).

  • Life-stage microbiome development: B. breve described as commonly dominant in healthy breast-fed infants, with age-related shifts in bifidobacterial species composition (observational/biological context rather than treatment).

2. Does it work in treating those conditions? Summarize the evidence.

  • MDD (B. breve CCFM1025): One small randomized study (n=45) reported greater improvement vs placebo on depression scales (HDRS-24 and MADRS) with moderate effect sizes (d ~0.64–0.65). The abstract also reports a larger reduction in “serum serotonin turnover” vs placebo and links effects to changes in gut microbiome features and tryptophan/indole metabolites. Limitations from the abstract: small sample size and single strain; outcomes and durability beyond the study period are not provided.

  • MCI (B. breve A1/MCC1274): Two RCTs suggest potential cognitive benefit.

    • 16-week RCT (n=80; 79 completed): RBANS total score improved significantly vs placebo (between-group difference 11.3; 95% CI 6.7–15.8; p<0.0001), with improvements in immediate memory, visuospatial/constructional, and delayed memory; no adverse events reported.

    • 24-week RCT (n=130; analysis set 115): Improvements were reported on some subscales (e.g., ADAS-Jcog “orientation”; MMSE subscales in a lower baseline MMSE subgroup). MRI analysis suggested probiotic supplementation tended to suppress progression of brain atrophy, particularly in those with more advanced baseline atrophy. The abstract notes limited sensitivity of cognitive tests for MCI and reports no marked overall gut microbiota composition change.

    Overall: evidence is promising but not definitive; benefits appear domain/subscale-specific in one trial and stronger on RBANS in another, with strain-specificity (A1/MCC1274) and older adult populations.

  • AD model mice (B. breve A1): In animals, oral B. breve A1 reversed cognitive/behavioral impairments (Y-maze alternation; passive avoidance latency). Non-viable components and acetate partially ameliorated decline, and hippocampal inflammatory/immune-reactive gene expression induced by amyloid-β was suppressed. Translation to humans with AD is not established by these abstracts.

  • Cognition in healthy mice (B. breve 1205): After 11 weeks, B. breve 1205 improved object recognition discrimination speed vs vehicle, but effects were smaller than those seen with B. longum 1714 in the same study. The authors explicitly caution that effects of individual Bifidobacteria strains do not generalize across a species.

  • CAC/colitis-driven tumorigenesis in mice (B. breve): B. breve alleviated colitis symptoms, delayed tumorigenesis, and shifted macrophage populations toward mature homeostatic phenotypes. Ablation of intestinal macrophages largely annulled protection, supporting a mechanistic role. The metabolite indole-3-lactic acid (ILA) was enriched/associated with B. breve and acted via AhR and AKT signaling in murine and human-derived macrophages in vitro; an AhR antagonist largely abrogated benefits in vivo. This is preclinical evidence; clinical efficacy in humans is not shown here.

3. What health benefits does it have?

  • Mood and gut–brain axis effects (strain-specific): In MDD, B. breve CCFM1025 improved depression scores and was linked to serotonergic/tryptophan-metabolism changes and gastrointestinal symptom factors (suggesting potential combined mood + GI benefits in that population).

  • Cognitive support (strain-specific): B. breve A1 (MCC1274) improved cognitive outcomes in suspected MCI in RCTs (notably RBANS total and memory-related domains in one trial) and may slow brain atrophy progression (MRI signal) in another.

  • Anti-inflammatory / immunomodulatory potential (preclinical): In AD model mice, B. breve A1 suppressed hippocampal inflammation/immune-reactive gene expression induced by amyloid-β. In CAC mice, B. breve promoted differentiation of inflammatory macrophages toward homeostatic macrophages, with ILA acting through AhR/AKT pathways.

  • Potential protective effects in inflammatory gut conditions (preclinical): In the CAC model, B. breve reduced colitis symptoms and delayed tumorigenesis; microbial analysis showed enrichment of “probiotics” and depletion of potential pathogens after supplementation.

  • General probiotic-related metabolic outputs (review-level): Reviews note bifidobacteria (including B. breve) are associated with production of potentially beneficial metabolites such as short-chain fatty acids and bacteriocins; however, the abstracts do not provide direct clinical outcome data for these endpoints specific to B. breve.

  • Early-life microbiome relevance (contextual): B. breve is described as commonly dominant in healthy breast-fed infants, consistent with a role in normal early microbiome development (not a treatment claim by itself).

4. Does it have any downsides or side effects?

  • Reported adverse events in the provided RCT: In the 16-week MCI trial of B. breve A1 (MCC1274), the abstract states no adverse events were observed.

  • GI effects (mixed/unclear): The MDD trial discusses gastrointestinal symptom factors and suggests GI problems may be affected (via serotonergic mechanisms), but the abstract does not clearly enumerate adverse GI side effects versus improvements.

  • Limitations/uncertainties rather than clear harms: Several abstracts emphasize strain-specificity and that effects do not generalize across strains/species; this is a practical downside for consumers because benefits seen with one strain (e.g., A1/MCC1274 or CCFM1025) cannot be assumed for other “B. breve” products.

  • Not addressed in these abstracts: Risks in immunocompromised individuals, rare bacteremia, product quality/contamination, and interactions with medications are not discussed in the provided text, so no evidence-based conclusion can be drawn here from these abstracts alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses (e.g., outcomes stratified by host genotype) for B. breve in depression, MCI, or other conditions.

  • Mechanistic pathways mentioned (not genotype-tested): The MDD trial implicates serotonergic signaling and tryptophan/indole metabolism; the CAC model implicates AhR and AKT signaling via indole-3-lactic acid. These pathways could plausibly vary by genetics, but the abstracts do not evaluate genetic variants (e.g., in serotonin transport/metabolism genes, AHR pathway genes) or differential responses.

  • Conclusion: No evidence from these abstracts that B. breve is specifically beneficial or harmful for particular genetic variants; pharmacogenomic relevance remains unknown based on the provided material.

References

  1. Temporal development of the gut microbiome in early childhood from the TEDDY study.
    Christopher J Stewart, Nadim J Ajami, Jacqueline L O'Brien, Diane S Hutchinson, Daniel P Smith, Matthew C Wong, Matthew C Ross, Richard E Lloyd, HarshaVardhan Doddapaneni, Ginger A Metcalf, Donna Muzny, Richard A Gibbs, Tommi Vatanen, Curtis Huttenhower, Ramnik J Xavier, Marian Rewers, William Hagopian, Jorma Toppari, Anette-G Ziegler, Jin-Xiong She, Beena Akolkar, Ake Lernmark, Heikki Hyoty, Kendra Vehik, Jeffrey P Krischer, Joseph F Petrosino (2018) - Nature
  2. Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial.
    Peijun Tian, Ying Chen, Huiyue Zhu, Luyao Wang, Xin Qian, Renying Zou, Jianxin Zhao, Hao Zhang, Long Qian, Qun Wang, Gang Wang, Wei Chen (2022) - Brain, behavior, and immunity
  3. Gut Bifidobacteria Populations in Human Health and Aging.
    Silvia Arboleya, Claire Watkins, Catherine Stanton, R Paul Ross (2016) - Frontiers in microbiology
  4. Recent Development of ProbioticBifidobacteriafor Treating Human Diseases
    Jun Chen, Xinyi Chen, Chun Loong Ho (2021)
  5. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer's disease.
    Yodai Kobayashi, Hirosuke Sugahara, Kousuke Shimada, Eri Mitsuyama, Tetsuya Kuhara, Akihito Yasuoka, Takashi Kondo, Keiko Abe, Jin-Zhong Xiao (2017) - Scientific reports
  6. Bifidobacteria modulate cognitive processes in an anxious mouse strain.
    H M Savignac, M Tramullas, B Kiely, T G Dinan, J F Cryan (2015) - Behavioural brain research
  7. Effect of Probiotics on Central Nervous System Functions in Animals and Humans: A Systematic Review.
    Huiying Wang, In-Seon Lee, Christoph Braun, Paul Enck (2016) - Journal of neurogastroenterology and motility
  8. Bifidobacterium breve-derived indole-3-lactic acid ameliorates colitis-associated tumorigenesis by directing the differentiation of immature colonic macrophages
    Yuke Li, Qingxiang Li, Ruoshui Yuan, Yifei Wang, Chuanbin Guo (2024)
  9. Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Daisuke Asaoka, Jinzhong Xiao, Tsutomu Takeda, Naotake Yanagisawa, Takahiro Yamazaki, Yoichiro Matsubara, Hideki Sugiyama, Noemi Endo, Motoyuki Higa, Koji Kasanuki, Yosuke Ichimiya, Shigeo Koido, Kazuya Ohno, Francois Bernier, Noriko Katsumata, Akihito Nagahara, Heii Arai, Toshifumi Ohkusa, Nobuhiro Sato (2022) - Journal of Alzheimer's disease : JAD
  10. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Jinzhong Xiao, Noriko Katsumata, Francois Bernier, Kazuya Ohno, Yuki Yamauchi, Toshitaka Odamaki, Kenji Yoshikawa, Kumie Ito, Toshiyuki Kaneko (2020) - Journal of Alzheimer's disease : JAD
  11. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.
    Shujie Wang, Huahui Ren, Huanzi Zhong, Xinjie Zhao, Changkun Li, Jing Ma, Xuejiang Gu, Yaoming Xue, Shan Huang, Jialin Yang, Li Chen, Gang Chen, Shen Qu, Jun Liang, Li Qin, Qin Huang, Yongde Peng, Qi Li, Xiaolin Wang, Yuanqiang Zou, Zhun Shi, Xuelin Li, Tingting Li, Huanming Yang, Shenghan Lai, Guowang Xu, Junhua Li, Yifei Zhang, Yanyun Gu, Weiqing Wang (2022) - Gut microbes
  12. Bifidobacterium breve HNXY26M4 Attenuates Cognitive Deficits and Neuroinflammation by Regulating the Gut-Brain Axis in APP/PS1 Mice.
    Guangsu Zhu, Jianxin Zhao, Gang Wang, Wei Chen (2023) - Journal of agricultural and food chemistry
  13. Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial.
    Arianna Solito, Nicole Bozzi Cionci, Matteo Calgaro, Marina Caputo, Lucia Vannini, Iderina Hasballa, Francesca Archero, Enza Giglione, Roberta Ricotti, Gillian Elisabeth Walker, Antonella Petri, Emanuela Agosti, Giorgio Bellomo, Gianluca Aimaretti, Gianni Bona, Simonetta Bellone, Angela Amoruso, Marco Pane, Diana Di Gioia, Nicola Vitulo, Flavia Prodam (2021) - Clinical nutrition (Edinburgh, Scotland)
  14. Age-Related Changes in the Composition of Gut Bifidobacterium Species.
    Kumiko Kato, Toshitaka Odamaki, Eri Mitsuyama, Hirosuke Sugahara, Jin-Zhong Xiao, Ro Osawa (2017) - Current microbiology
  15. Effect of bifidobacterium breve A-1 on anxiety and depressive symptoms in schizophrenia: A proof-of-concept study.
    Ryo Okubo, Minori Koga, Noriko Katsumata, Toshitaka Odamaki, Shiina Matsuyama, Matsuhiko Oka, Hisashi Narita, Naoki Hashimoto, Ichiro Kusumi, Jinzhong Xiao, Yutaka J Matsuoka (2019) - Journal of affective disorders
  16. Investigating the therapeutic potential of
    Nafiseh Erfanian, Hossein Safarpour, Tahmineh Tavakoli, Mohammad Ali Mahdiabadi, Saeed Nasseri, Mohammad Hassan Namaei (2024) - Iranian journal of microbiology
  17. Inflammatory Manifestations Associated With Gut Dysbiosis in Alzheimer's Disease.
    Samat Kozhakhmetov, Aiym Kaiyrlykyzy, Zharkyn Jarmukhanov, Elizaveta Vinogradova, Gulnaz Zholdasbekova, Dinara Alzhanova, Jeanette Kunz, Almagul Kushugulova, Sholpan Askarova (2024) - International journal of Alzheimer's disease
  18. The Combined Effect of Potential Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 Towards Anti-inflammatory Activity on HT-29 Cell Lines.
    Rohith H S, Prakash Motiram Halami (2023) - Probiotics and antimicrobial proteins
  19. A synbiotic mixture of
    Gillina F G Bezemer, Mara A P Diks, Esmaeil Mortaz, Ingrid van Ark, Jeroen van Bergenhenegouwen, Aletta D Kraneveld, Gert Folkerts, Johan Garssen (2024) - Frontiers in nutrition
  20. Bifidobacteria exert species-specific effects on constipation in BALB/c mice.
    Linlin Wang, Lujun Hu, Qi Xu, Tian Jiang, Shuguang Fang, Gang Wang, Jianxin Zhao, Hao Zhang, Wei Chen (2017) - Food & function


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!